Perspective Therapeutics, Inc. (CATX) Stock Analysis & Investment Frameworks
Perspective Therapeutics, Inc. (CATX) stock analysis on Invetso. Review Perspective Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Perspective Therapeutics, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Perspective Therapeutics, Inc. Key Financial Metrics
- Market Cap: $95.89M
- Revenue: $N/A
- ROE: -41.56%
- ROIC: -34.94%
- Dividend Yield: N/A
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.